Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01997905
Other study ID # CP2011-2
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received November 21, 2013
Last updated August 24, 2015
Start date January 2014
Est. completion date August 2015

Study information

Verified date August 2015
Source AtriCure, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This is a feasibility study to assess the safety and efficacy of the AtriCure AtriClip when placed via Minimally Invasive Surgical Deployment to the Left Atrial Appendage. The purpose is for evaluation of Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation who are unable to take Oral Anticoagulants.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date August 2015
Est. primary completion date July 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. Patient is = 18 years and = 80 years of age.

2. Patient has electrocardiographically confirmed non-valvular atrial fibrillation (paroxysmal, persistent, or longstanding persistent AF).

3. CHADS2 or CHA2DS2VASc score =2.

4. Patient has medical contraindication to long term anticoagulant therapy (OAC), defined as one or more of the following:

- history of intracranial bleeding (e.g. due to amyloid angiopathy or other condition) which renders patient unsafe for OAC;

- history of gastrointestinal, genitourinary, or respiratory tract bleeding due to permanent condition which renders patient unsafe for OAC;

- HAS-BLED Score = 3.

5. Patient is considered an acceptable surgical candidate, including use of general anesthesia.

6. Female patients must be of non-child bearing potential, or have a negative pregnancy test within 7 days prior to index procedure.

Exclusion Criteria:

1. Stroke within 30 days, or TIA within 3 days, respectively, prior to index procedure.

2. Documented medical history of any penetrating trauma to thorax, or blunt trauma to thorax which resulted in a left pneumothorax or left hemothorax.

3. Myocardial infarction within 60 days prior to index procedure.

4. NYHA Class IV heart failure.

5. Ejection fraction < 40% (based on baseline transthoracic echocardiography (TTE)).

6. Prior attempted obliteration of left atrial appendage (percutaneous or open cardiac surgery).

7. Previous catheter ablation with perforation or complication.

8. Prior open cardiac surgery, or percutaneous coronary intervention with associated unintended cardiac perforation, or pericardial adhesions are suspected.

9. History of pericarditis or pericardiocentesis.

10. Active infection, septicemia, or fever of unknown origin.

11. Concomitant elective surgical procedure (in addition to AtriClip placement) at the time of index procedure.

12. Planned atrial arrhythmia ablation procedure within six months following index procedure.

13. Underlying structural heart disease requiring planned surgical treatment within six months following the index procedure.

14. Cardiac or thoracic surgical procedure within the thirty days prior to index procedure.

15. Anticoagulation therapy for other medical condition (i.e. deep vein thrombosis) is required.

16. Patient unable to discontinue thienopyridines (e.g. clopidogrel) or non-ASA antiplatelet agents 4 days pre-operatively and abstain for at least 2 days post-operatively.

17. Renal Failure as defined by creatinine > 2.0 mg/dl (> 152.5 umol/L) and/or need for dialysis.

18. Known carotid artery diameter stenosis greater than 80%.

19. Patient has symptomatic or high-grade carotid disease (>70% bilaterally).

20. Patient unable or unwilling to undergo transesophageal echocardiography (TEE).

21. Presence of thrombus in the left atrium or LAA, as determined by baseline TTE or Computed Tomography Angiogram (CTA).

22. Documented history of thrombophilic disorder, with diagnosis established via previous objective testing (e.g. familial screening for thrombophilia).

23. Moderate to Severe Chronic Obstructive Pulmonary Disease (FEV1 or VC<70% predicted) or intolerant of single lung ventilation.

24. History of Hypercoagulopathy

25. Body Mass Index (BMI) > 35.

26. Other medical illness or comorbidity that may cause non-compliance with the protocol, confound data interpretation (e.g. severe dementia), or limited life expectancy (i.e. < 3 months).

27. Enrolled in another investigational device or drug study at the time of enrollment and during the course of the study.

28. Psychiatric disorder which in the judgment of the investigator could interfere with informed consent, completion of tests, therapy, or follow-up.

29. Patient is pregnant or intends to become pregnant within 6 months post-index procedure.

Intraoperative Exclusion Criteria

1. Left atrial appendage width < 29mm or > 50mm, based on TEE imaging.

2. Presence of thrombus in the left atrium or LAA based on TEE imaging.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
AtriClip LAA Exclusion Device


Locations

Country Name City State
United States University of Virginia Charlottesville Virginia
United States Good Samaritan Hospital Cincinnati Ohio
United States Houston Methodist Hospital Houston Texas
United States Franciscan St. Francis Health Indianapolis Indiana
United States Mercy Hospital Miami Florida
United States St. Helena Hospital St. Helena California
United States Aspirus Wausau Wisconsin

Sponsors (1)

Lead Sponsor Collaborator
AtriCure, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Serious Adverse Events within 30 Days Post-Index Procedure The primary safety endpoint consists of the following serious adverse events within 30 days post-index procedure (unless otherwise noted), as adjudicated by Independent Physician Adjudicator:
Serious Injury to the cardiac structure or other body structure deemed to be related to the delivery or placement of the Clip
Cardiac-Related Death, Myocardial Infarction, or Ischemic Stroke
Major bleeding (defined as requiring re-operation and/or transfusion (> 2 U packed red blood cells (PRBC)) within any 24 hour period during the first 2 days post-index procedure or at any time point if attributed to the device/index procedure).
30 days post-index procedure Yes
Primary Composite Left Atrial Appendage Placement and Exclusion success Primary Efficacy endpoint is a success/failure endpoint with success requiring all of the following:
Patient Technical Success: The ability to successfully implant an AtriClip device at the LAA in a patient.
Intra-Procedural Complete Exclusion of the LAA: The complete exclusion of the LAA defined by lack of fluid communication (<3 mm residual communication with LAA and <10 mm residual pocket) between the LA and LAA, assessed intra-procedurally by TEE.
3 Month Follow-Up Complete Exclusion of the LAA: The complete exclusion of the LAA defined by lack of fluid communication (<3 mm residual communication with LAA and < 10mm residual pocket) between the LA and LAA at >=3 month TEE or CTA evaluation.
Immediate to 3-months post-index procedure No
Secondary Rate of Stroke and Non-CNS systemic embolism The secondary efficacy endpoints will be a composite of the following events within 3 months and 6 months post-index procedure:
Stroke (ischemic )
Non-CNS (Central Nervous System) systemic embolism.
3 months and 6 months post-index procedure Yes
Secondary Serious Device or Procedure Related Adverse Event Rate Overall Serious Device or Procedure Related Adverse Event Rate: Incidence of all serious device or procedure related adverse events observed through the 3 month and 6 month follow-up assessments as adjudicated by Independent Physician Adjudicator. 3 month and 6 month post-index procedure Yes
Secondary Overall Serious Adverse Event Rate Overall Serious Adverse Event Rate: Incidence of all serious adverse events, regardless of attribution, observed through the 3 month and 6 month follow-up assessments, as adjudicated by Independent Physician Adjudicator. 3 month and 6 month Post Index Procedure Yes
Secondary Overall Adverse Event Rate Overall Adverse Event Rate: Incidence of all device and procedure related adverse events and any neurological related AEs, regardless of attribution, observed through the 3 month and 6 month follow-up assessments, as adjudicated by Independent Physician Adjudicator. 3 month and 6 month post-index procedure Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Completed NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Completed NCT05366803 - Women's Health Initiative Silent Atrial Fibrillation Recording Study N/A
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Recruiting NCT05442203 - Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease N/A
Completed NCT05599308 - Evaluation of Blood Pressure Monitor With AFib Screening Feature N/A
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Enrolling by invitation NCT05890274 - Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO N/A
Recruiting NCT05316870 - Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation N/A
Recruiting NCT05266144 - Atrial Fibrillation Patients Treated With Catheter Ablation
Not yet recruiting NCT06023784 - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT06283654 - Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A